Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XLRN
Previous Symbol
CUSIPN/A
Phone617-649-9200
Debt
Debt-to-Equity RatioN/A
Current Ratio21.68
Quick Ratio21.68
Price-To-Earnings
Trailing P/E Ratio-17.30
Forward P/E Ratio-18.47
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.48 million
Price / Sales158.89
Cash FlowN/A
Price / Cash FlowN/A
Book Value$8.07 per share
Price / Book5.75
Profitability
EPS (Most Recent Fiscal Year)($2.68)
Net Income$-108,450,000.00
Net Margins-807.36%
Return on Equity-32.69%
Return on Assets-30.94%
Miscellaneous
Employees139
Outstanding Shares46,190,000
Market Cap$2.21 billion
OptionableOptionable
Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions
What is Acceleron Pharma's stock symbol?
Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."
How were Acceleron Pharma's earnings last quarter?
Acceleron Pharma Inc (NASDAQ:XLRN) posted its quarterly earnings data on Tuesday, October, 30th. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the Zacks' consensus estimate of ($0.66) by $0.03. The biopharmaceutical company had revenue of $3.30 million for the quarter, compared to analyst estimates of $4.37 million. Acceleron Pharma had a negative net margin of 807.36% and a negative return on equity of 32.69%. The business's revenue for the quarter was up 10.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.65) earnings per share. View Acceleron Pharma's Earnings History.
When is Acceleron Pharma's next earnings date?
What price target have analysts set for XLRN?
11 analysts have issued twelve-month price targets for Acceleron Pharma's shares. Their predictions range from $33.00 to $75.00. On average, they anticipate Acceleron Pharma's share price to reach $56.20 in the next twelve months. This suggests a possible upside of 21.2% from the stock's current price. View Analyst Price Targets for Acceleron Pharma.
What is the consensus analysts' recommendation for Acceleron Pharma?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 4 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acceleron Pharma.
Has Acceleron Pharma been receiving favorable news coverage?
News articles about XLRN stock have been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Acceleron Pharma earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
Who are some of Acceleron Pharma's key competitors?
Some companies that are related to Acceleron Pharma include Qiagen (QGEN), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), bluebird bio (BLUE), Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Crispr Therapeutics (CRSP) and Aerie Pharmaceuticals (AERI).
Who are Acceleron Pharma's key executives?
Acceleron Pharma's management team includes the folowing people:
- Mr. Habib J. Dable, CEO, Pres & Director (Age 49)
- Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 75)
- Mr. Kevin F. McLaughlin, CFO, Sr. VP & Treasurer (Age 62)
- Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 58)
- Dr. John D. Quisel, Exec. VP, Chief Bus. Officer & Sec. (Age 47)
Who are Acceleron Pharma's major shareholders?
Acceleron Pharma's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.94%), BlackRock Inc. (9.41%), Vanguard Group Inc. (7.42%), Vanguard Group Inc (7.42%), Janus Henderson Group PLC (3.02%) and Artal Group S.A. (2.16%). Company insiders that own Acceleron Pharma stock include Christopher Rovaldi, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Richard F Pops and Steven D Ertel. View Institutional Ownership Trends for Acceleron Pharma.
Which institutional investors are selling Acceleron Pharma stock?
XLRN stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Artal Group S.A., AXA, Baker BROS. Advisors LP, Pictet Asset Management Ltd., Prudential Financial Inc., Foresite Capital Management III LLC and Foresite Capital Management II LLC. Company insiders that have sold Acceleron Pharma company stock in the last year include Christopher Rovaldi, Habib J Dable, Jean George, John D Quisel, Kevin F Mclaughlin, Matthew L Sherman and Richard F Pops. View Insider Buying and Selling for Acceleron Pharma.
Which institutional investors are buying Acceleron Pharma stock?
XLRN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc, Vanguard Group Inc., Federated Investors Inc. PA, Janus Henderson Group PLC, BlackRock Inc., Stanley Laman Group Ltd. and EAM Investors LLC. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.
How do I buy shares of Acceleron Pharma?
Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acceleron Pharma's stock price today?
One share of XLRN stock can currently be purchased for approximately $46.37.
How big of a company is Acceleron Pharma?
Acceleron Pharma has a market capitalization of $2.21 billion and generates $13.48 million in revenue each year. The biopharmaceutical company earns $-108,450,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Acceleron Pharma employs 139 workers across the globe.
What is Acceleron Pharma's official website?
How can I contact Acceleron Pharma?
Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]
MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe XLRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XLRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
